YAP/TAZ are nuclear effectors of the Hippo pathway regulating organ growth and tumorigenesis. Yet, their function as transcriptional regulators remains underinvestigated. By ChIP-seq analyses in breast cancer cells, we discovered that the YAP/TAZ transcriptional response is pervasively mediated by a dual element: TEAD factors, through which YAP/TAZ bind to DNA, co-occupying chromatin with activator protein-1 (AP-1, dimer of JUN and FOS proteins) at composite cis-regulatory elements harbouring both TEAD and AP-1 motifs. YAP/TAZ/TEAD and AP-1 form a complex that synergistically activates target genes directly involved in the control of S-phase entry and mitosis. This control occurs almost exclusively from distal enhancers that contact target promoters through chromatin looping. YAP/TAZ-induced oncogenic growth is strongly enhanced by gain of AP-1 and severely blunted by its loss. Conversely, AP-1-promoted skin tumorigenesis is prevented in YAP/TAZ conditional knockout mice. This work highlights a new layer of signalling integration, feeding on YAP/TAZ function at the chromatin level.
. Yet, the mechanisms underpinning this activity remain enigmatic. Only a handful of direct targets have been described in mammalian cells, leaving largely undefined what are the immediate downstream effectors by which YAP/TAZ exert their biological effects 3 . Moreover, lack of systematic studies results in just a scattered understanding of the transcriptional partners by which nuclear YAP/TAZ control transcription on a genome-wide scale. Also unknown is whether and how, after binding to DNA, YAP/TAZ achieve combinatorial control of gene expression, for example through cooperation with other nuclear oncogenes during YAP/TAZ-driven oncogenic growth.
RESULTS

A genomic map of YAP/TAZ recruitment to chromatin
To elucidate how YAP/TAZ regulate gene expression in tumour cells we performed chromatin immunoprecipitation assays with YAP and TAZ antibodies followed by next-generation sequencing (ChIP-seq) in MDA-MB-231 breast cancer cells, bearing genetic inactivation of the Hippo pathway (NF2 null) 7 . A total of 7,107 peaks were identified by both antibodies (Fig. 1a) . YAP/TAZ-bound regions included the promoters of previously established YAP/TAZ direct targets (CTGF, CYR61, ANKRD1, AXL, AMOTL2, AJUBA and WTIP, Supplementary Fig. 1b-d) .
YAP/TAZ do not carry a DNA-binding domain, and thus can contact the DNA only indirectly, through transcription factor partners. So far, a number of these partners have been described, including TEAD1-4, RUNX, p73, KLF4, TBX5 and others 3, [8] [9] [10] [11] . Motif analyses at YAP/TAZ peaks revealed that the main platforms by which YAP/TAZ interact with DNA are TEAD proteins: their consensus sequence was present in at least 75% of YAP/TAZ peaks, typically at the summit of YAP/TAZ peaks ( Supplementary Fig. 1e ,f). TEAD factors have been repeatedly associated as mediators of YAP/TAZ transcriptional responses 3, 9 ; surprisingly no motifs for the other proposed DNA-binding platforms of YAP/TAZ were significantly enriched (with the exception of RUNX, found in a minority of peaks; see Supplementary Table 1) .
Following these results, we performed a ChIP-seq experiment for endogenous TEAD4 and found that 78% (5,522) of YAP/TAZ peaks overlapped with TEAD4 peaks (Fig. 1b and Supplementary  Table 2) ; furthermore, the summits of TEAD4 peaks coincide with the summit of the corresponding YAP/TAZ peaks (Fig. 1c) , indicating that TEAD factors are indeed the main driver for YAP/TAZ recruitment to chromatin. In support of this notion, the signal of TEAD4 peaks R E S O U R C E is positively correlated with that one of YAP/TAZ peaks (Fig. 1d) , and binding of YAP to chromatin is strongly affected by combined knockdown of TEAD1/2/3/4 as assessed by ChIP-qPCR (Fig. 1e ).
Global association of YAP/TAZ/TEAD to enhancer elements
We analysed the distribution of YAP-, TAZ-or TEAD-binding sites relative to genes annotated in the human genome, and found that only a minute fraction of peaks mapped close (±1 kilobase (kb)) to transcription start sites (TSSs) whereas most peaks were located farther than 10 kb from the closest TSS (Fig. 1f) . Analyses of publicly available TEAD ChIP-seq data revealed that this pattern is conserved in several cancer cell types ( Supplementary Fig. 1i ).
Owing to their remote location, we questioned whether most YAP/TAZ/TEAD common peaks are located in enhancers. Enhancers CCNA2  CDC25A  CDC6  CDCA5  CDCA8  CENPF  CENPV  EDN1  ETS1  ETS2  FOSL1  GADD45B   GINS1  KIF14  KIF20B  KIF23  KNTC1  MCM3  MCM7  MRE11A  MYBL1  MYC  POLA2  POLE3  POLH  PSMC3IP  PSMG1  RAD18  RRM2  RUVBL2  SGOL1  SMC3  SUV39H2  TIMELESS   TK1  TOP2A  TUBB can be distinguished from promoters by their epigenetic features, that is, relative enrichment of histone H3 monomethylation (H3K4me1) on Lys 4 at enhancers, and trimethylation (H3K4me3) at promoters 12 . ChIP-seq data for these epigenetic marks in MDA-MB-231 cells were recently reported 13 , allowing us to compare this map of promoters and enhancers with the location of YAP/TAZ/TEAD4 peaks (Fig. 1g) . Notably, only a very small fraction (3.6%) of YAP/TAZ/TEAD4 peaks are located on promoters; instead, 91% of peaks are located in enhancer regions (Fig. 1h,i) . Furthermore, most of these enhancers are in an active state as revealed by H3K27 acetylation and reduced nucleosome occupancy at the peak centre, also resulting in a bimodal distribution of H3K4me1 around the peak summit (Fig. 1h-j and Supplementary Fig. 1k) .
A YAP/TAZ-regulated transcriptional program driving cell proliferation
We then sought to link YAP/TAZ/TEAD4 peaks to corresponding target genes ( Supplementary Fig. 1l ). All of the peaks located in promoter regions (201) were assigned to the nearest genes. However, application of this proximity criterion to the distant enhancers bound by YAP/TAZ was questionable, as enhancers can regulate target genes over long distances, often skipping intervening genes. Instead, the specificity of enhancer-promoter associations is dictated by the threedimensional higher-order chromatin structure, whereby enhancers interact with their target promoters through chromatin looping 12 . Importantly, a recently reported high-resolution map of chromatin interactions (Hi-C) has been shown to predict bona fide enhancerpromoter pairs with great accuracy 14 . Notably, most of these longrange chromatin interactions are conserved across cell types 15 . By using the map of enhancer-promoter pairs discovered in ref. 14, we could associate more than half of YAP/YAZ/TEAD4-bound enhancers to a set of 2,957 candidate target genes; considering also the genes with peaks in their promoters, the list extends to 3,089 genes. Of these candidates, 379 are in fact expressed in MDA-MB-231 cells, and in a YAP/TAZ-dependent manner, as determined by Affymetrix profiling of control and YAP/TAZ-depleted cells (using two independent combinations of siRNAs; Supplementary Table 3) . Crucially, most (88.6%) of these bona fide YAP/TAZ direct targets are controlled only from distal enhancers, mostly located farther than 100,000 base pairs (bp) from the TSS (Fig. 1k) ; we further note that these genes could not have been identified by assigning the peak to the closest gene.
To identify the main biological processes regulated by YAP/TAZ, we performed Gene Ontology (GO) analyses on the list of YAP/TAZ direct targets. A large fraction of positive targets (135) are linked to processes related to cell cycle progression (Fig. 2a and Supplementary  Tables 4 and 5) ; YAP/TAZ/TEAD-binding sites are located exclusively on distal enhancers for 115 of these genes, and both on promoters and enhancers for other 11 genes. Other positive targets (13.5% of the total) are connected to RNA metabolism and RNA transport.
The YAP/TAZ/TEAD cell-proliferation program comprises essential factors involved in replication licensing, DNA synthesis and repair (for example, CDC6, GINS1, MCM3, MCM7, POLA2, POLE3, TOP2A and RAD18), transcriptional regulators of the cell cycle (for example, ETS1, MYC and MYBL1), cyclins and their activators (CCNA2 and CDC25A), and factors required for completion of mitosis (for example, CENPF, CDCA5 and KIF23). We selected about 40 of these genes (containing representative genes belonging to each of the above-mentioned categories) and confirmed by quantitative PCR with reverse transcription (qRT-PCR) that their expression depends on YAP/TAZ as well as on TEAD1-4 (Fig. 2b) . All of these new YAP/TAZ/TEAD-regulated genes were associated to YAP/TAZ/TEAD peaks located on enhancers (as exemplified in Supplementary Fig. 2c ). By chromatin conformation capture (3C) analysis we confirmed that the interaction of YAP/TAZ/TEAD-bound enhancers with MYC or TOP2A promoters occurs through chromatin looping in MDA-MB-231 cells (Fig. 2c,d and Supplementary  Fig. 2d,e) , validating the procedure here used to associate distant enhancers to target genes by using Hi-C data. Remarkably, YAP/TAZ are required for the activity of these enhancers, as acetylation of H3K27 in these regions drops in YAP/TAZ-depleted cells (Fig. 2e) .
We next aimed to determine the biological validity of these findings. We found that YAP/TAZ-depleted cells stop proliferating and accumulate in the G 1 phase (Fig. 3a,b) . These effects are phenocopied by TEAD depletion ( Supplementary Fig. 3b,c) ; moreover, the growth of YAP/TAZ-depleted cells can be fully rescued by reintroduction of wild-type YAP or TAZ, but not by their TEAD-binding-deficient mutants ( Fig. 3c and Supplementary Fig. 3d ). Together, these results underline the relevance of TEAD as the master determinant of YAP/TAZ-driven proliferation 9 . To investigate the newly identified YAP/TAZ direct targets, we focused on MYC, given its established prominence as a regulator of cell proliferation. As shown in Supplementary Fig. 3e -g, MYC knockdown caused a minor, but significant reduction of cell proliferation and a substantial increase of cells in the G 1 phase, in part phenocopying the requirement of YAP/TAZ. Overexpression of MYC in YAP/TAZdepleted cells triggered a significant, but only a partial rescue of cell proliferation (Fig. 3d) . This indicates that MYC represents an important functional effector of YAP/TAZ in this context; however, MYC alone cannot fully recapitulate the biological effectiveness of YAP/TAZ.
We next sought to determine whether genes identified as YAP/TAZ/TEAD targets in MDA-MB-231 cells are exploited in human breast cancers. YAP/TAZ are required and sufficient to confer malignant traits to more benign tumour cells [16] [17] [18] . In line, elevated levels of YAP/TAZ in human breast cancer specimens identify aggressive tumours (defined as high histopathological grade, or 'G3'), and those with worse prognosis 16 . Direct targets of YAP/TAZ/TEAD should thus similarly earmark aggressive tumours and be prognostic. To test this idea, we used a data set of >3,600 clinically annotated and transcriptionally profiled breast cancer samples (Supplementary Table 8 ) and confirmed that the signature enlisting the validated YAP/TAZ/TEAD direct targets (see Fig. 2b ) was differentially expressed in G3 and G 1 tumours, and identified tumours with poor prognosis as determined by Kaplan-Meier analyses (Fig. 3e,f) . Moreover, the signature of direct targets statistically correlates with the expression of independent YAP/TAZ signatures, and with the levels of TAZ messenger RNA, which is amplified in a subset of breast tumours 16, 19 ( Supplementary Fig. 3i ). Thus, the expression of direct YAP/TAZ/TEAD target genes here identified correlates with YAP/TAZ activation in human tumours. We next verified that AP-1 factors are indeed recruited to the same genomic regions bound by YAP/TAZ/TEAD4. For this, we considered JUN as a surrogate mark for bound AP-1 dimers, because it is a common component of JUN/FOS and JUN/JUN dimers 20 . By ChIPseq we identified >24,000 JUN-binding sites. JUN was present in 78% of YAP/TAZ/TEAD-binding sites (4,306/5,522; Fig. 4a,b) , and 93% of these shared binding sites are located on active enhancers. This is in line with the notion that composite TEAD and AP-1 motifs dominate the YAP/TAZ cistrome. JUN peaks were detected on the regulatory regions of wellestablished YAP/TAZ/TEAD target genes (CTGF and ANKRD1- Supplementary Fig. 4c) , and on the enhancers of 85% of the new targets defining the YAP/TAZ/TEAD cell-proliferation program (as in Fig. 4c ). We indeed re-validated by ChIP-qPCR the presence of both JUN and FOSL1 in all tested binding sites ( Supplementary Fig. 4d,e) . By considering ChIP-seq data from the ENCODE project 21 , TEAD4 and AP-1 peaks largely overlap in all examined tumour cell lines ( Supplementary Fig. 4f,g ), indicating that co-occupancy of TEAD and AP-1 transcription factors on the same regions is a widespread phenomenon. To test the possibility that AP-1 proteins and YAP/TAZ can simultaneously co-occupy chromatin, we carried out a sequential ChIP for YAP followed by anti-JUN reChIP at selected loci. The results indicated that both factors co-occupy the same cis-regulatory elements at the same time (Fig. 4d) .
Given their vicinity on DNA, we tested whether YAP/TAZ, TEAD and AP-1 proteins could physically interact. By in situ proximity ligation assay 22 , we found YAP and TEAD1 in close proximity with Supplementary Fig. 5g ). Finally, we monitored the capacity of YAP to activate a luciferase reporter containing polymerized TEAD-binding sites (8xGT-LUX) or AP-1-binding sites. Despite being artificial, these reporters are highly specific and sensitive, and allow evaluation of the contribution of individual transcription factors in the absence of other, and potentially confounding, binding sites (a risk of natural promoters). YAP could activate 8xGT-LUX but not the AP-1 sensor (which instead was activated by treatment with the phorbol ester TPA, an established inducer of AP-1; Supplementary Fig. 5h,i) . Collectively, our results argue against the possibility that AP-1 dimers mediate YAP/TAZ binding to DNA; that said, it remains possible that, in certain contexts, AP-1 factors may also interact with YAP/TAZ to further enhance the stability of the YAP/TAZ-TEAD and AP-1 complex.
To assess the role of AP-1 in YAP/TAZ/TEAD-mediated transcription, we generated luciferase reporters containing CTGF and ANKRD1 regulatory sequences; both contain motifs for TEAD and AP-1. Mutation of either the TEAD or AP-1 motif reduces luciferase activity (Fig. 4i ), indicating that both sites are required to mediate YAP/TAZ-dependent transcription. Taken together, the data indicate that, at YAP/TAZ-bound cis-regulatory elements, YAP/TAZ/TEAD and AP-1 proteins form a transcription factor complex bound to composite regulatory elements harbouring both TEAD and AP-1 motifs (Fig. 4j) , and jointly regulate gene transcription. CCNA2  CDC25A  CDCA5  CDCA8  CENPV  ETS1  GINS1  GINS2  KATNB1  KIF20B  KIF23  MCM3  MCM7  MYBL1  POLA2  POLE3  PSMG1  RAD18  RRM2  RUVBL2  SGOL1 MDA-MB-231 cells, partially phenocopying the effects of YAP/TAZ depletion or TEAD1/2/3/4 depletion ( Supplementary Fig. 6b) .
The above findings raise the possibility that the oncogenic properties of YAP/TAZ may require AP-1. It has been previously reported that overexpression of TAZ confers 'cancer stem cell' properties to benign MII breast cancer cells 16, 25 . We first investigated whether AP-1 factors are involved in these effects. As shown in Fig. 5b , siRNA-mediated depletion of FOSL1, FOSL2, JUN or JUND severely reduced mammosphere formation by MII-TAZS89A cells, indicating that AP-1 factors are essential for these biological activities of TAZ.
Next, we tested whether AP-1 factors are instrumental to enhance YAP/TAZ activity during transformation and oncogenic growth. For this, we transduced immortalized non-tumorigenic mammary epithelial cells (MCF10A) with the following cDNAs: a JUN∼FOSL1 tethered dimer alone 26 (+AP-1 in Fig. 5c-h ), YAP5SA alone, or the two constructs together. By monitoring anchorage-independent growth in soft-agar and mammosphere assays, we found that concomitant expression of YAP and the AP-1 dimer strongly enhanced the number and size of colonies when compared with YAP alone (Fig. 5c,d) . No colonies were induced by AP-1 alone. Notably, the synergism between YAP and AP-1 requires YAP binding to TEAD, as no soft-agar colonies or mammospheres formed on expression of YAP5SA/S94A (which cannot interact with TEAD), irrespectively of the expression of AP-1 (Fig. 5c,d) .
To investigate whether the cooperation between YAP and AP-1 is important for induction of tumorigenic properties, we injected the MCF10A variants described above into the fat-pad of immunocompromised mice. As shown in Fig. 5e -g, expression of AP-1 was per se insufficient to induce tumours, but strongly enhanced the growth of YAP-induced tumours, as indicated by tumour size and Ki67 staining. Mice injected with cells expressing TEAD-bindingdeficient YAP instead developed no tumours, irrespectively of the expression of AP-1 dimer (Fig. 5f) . Importantly, the functional synergism between AP-1 proteins and YAP/TAZ/TEAD on tumour growth is a mirror of their transcriptional cooperation: although AP-1 dimer alone was insufficient to turn on the YAP/TAZ/TEAD proliferative program, it strongly synergized with YAP to activate transcription of these genes (Fig. 5h) . Collectively, results of gain-and loss-of-function assays indicate that AP-1 factors are instrumental for YAP/TAZ transcriptional and biological effects. . We thus sought to determine whether YAP/TAZ deficiency phenocopies the requirement of AP-1 in tumour promotion. To test this, we treated adult K14-CreERT2;YAP fl/fl ;TAZ fl/+ mice 33 with tamoxifen to inactivate YAP/TAZ in the skin basal layer; these mice were phenotypically normal, and their epidermis was histologically indistinguishable from wild-type controls ( Fig. 6b and Supplementary  Fig. 6e ). Control and YAP/TAZ-deficient mice were subjected to the chemical carcinogenesis protocol. As shown in Fig. 6a , at 40 weeks all control mice developed papillomas (average 9.3 tumours per mouse, n = 9). Strikingly, YAP/TAZ-deficient mice (which still had a normal skin after YAP/TAZ inactivation) developed only rare papillomas (1.5 tumours per mouse, n = 9), and 2 mice did not develop any tumours. Histological examination confirmed that control mice mostly developed typical papillomas or, more rarely, foci of squamous cell carcinomas; in contrast, the treated epidermis of K14-CreERT2;YAP fl/fl ;TAZ fl/+ mice retained normal morphology ( Fig. 6b and Supplementary Fig. 6e ). These results complement the above findings on the role of AP-1 for YAP/TAZ-induced tumour growth in mammary cells, and show that YAP/TAZ play a crucial role in the DMBA/TPA model of skin tumorigenesis, thus phenocopying the requirement of AP-1 in chemical carcinogenesis of the skin.
DISCUSSION
By carrying out genome-wide analyses of YAP/TAZ-binding sites in breast cancer cells through ChIP-seq, we found that most (91%) YAP/TAZ-bound cis-regulatory regions coincide with enhancer elements, located distant from TSSs. This provides a departure from all previous studies on this topic, so far centred exclusively on promoters 9 , allowing us to capture new and essential aspects of YAP/TAZmediated transcriptional regulation. By using this list of YAP/TAZ genomic interactions, a map of enhancer-promoter pairs and transcriptomic analyses of YAP/TAZ-dependent genes, we unveiled a complex repertoire of direct YAP/TAZ downstream effectors devoted to the control of cell proliferation, a critical process in most YAP/TAZdependent biological events. Many YAP/TAZ targets are proteins directly involved in specific steps of the cell cycle. Of these genes, only one (CDC6) was previously proposed as a direct YAP/TAZ target 34 . The program also includes transcription factors, such as MYC, potentially able to amplify the effects of YAP/TAZ. Overall, our work massively extends the previous knowledge on the transcriptional regulation of cell proliferation by YAP/TAZ and highlights yet unexplored aspects of YAP/TAZ biology, as well as a host of new therapeutic targets. The biological significance of these findings is further emphasized by the clinical validity of a signature of YAP/TAZ target genes as a prognostic tool in a large set of breast cancer patients.
The transcriptional responses of YAP/TAZ bear at least superficial similarities with the role of E2F factors: both are required for G 1 -to-S transition by directly controlling the molecular engines essential for DNA replication. Indeed, by ChIP-PCR experiments mainly using overexpressed YAP and TEAD it has been recently suggested that YAP/TEAD cooperate with E2F in the regulation of some genes from promoters potentially bearing composite TEAD-and E2F-binding consensuses 34 . However, at the genome-wide level, our data at the endogenous protein level do not favour this model, as the E2F consensus is not enriched at YAP/TAZ/TEAD-bound regions (Supplementary Table 1 ). That said, the E2F motif is present in a number of promoters of genes here identified in the YAP/TAZ-proliferative program (67%, Supplementary Table 5 ). Collectively, this raises the intriguing hypothesis that YAP/TAZ/TEAD bound to distant enhancers may cooperate with E2F bound to promoters through chromatin looping, thus possibly explaining the requirement of E2F for YAP-mediated cell proliferation 34 . Future work will be required to dissect this model. A plethora of DNA-binding platforms have been reported for YAP/TAZ (refs 3,8-11). Our ChIP-seq analyses indicate that TEAD factors are the anchors that tether YAP/TAZ to DNA at the genomewide level; functionally, TEADs are essential for the execution of the entire YAP/TAZ-dependent cell-proliferation program. Surprisingly, of the various transcription factors proposed to work as YAP/TAZ DNA-binding platforms, only the RUNX1/2 motif exhibits a low albeit significant enrichment in our context (Supplementary Table 1 ) but it is not preferentially enriched close to the summit of YAP/TAZ peaks; this suggests that, in general, RUNX factors are unlikely to serve as YAP/TAZ DNA-binding platforms.
A key finding of our genome-wide analyses is that AP-1 factors are critical and global regulators of YAP/TAZ/TEAD-dependent gene expression. AP-1 are present in most YAP/TAZ/TEAD-binding sites, forming a transcription factor complex bound to composite regulatory elements harbouring both the TEAD and the AP-1 motifs. AP-1 factors do not mediate YAP/TAZ DNA-recognition, and cannot sustain YAP/TAZ activities in the absence of YAP/TAZ binding to TEAD; instead AP-1 transcription factors strongly support YAP/TAZ/TEADdependent gene expression and greatly enhance oncogenic growth triggered by YAP. Conversely, AP-1 inactivation blunts the proliferative and cancer stem cell properties induced by TAZ. It is interesting to note that YAP/TAZ directly activate FOSL1 (Fig. 2b and Supplementary Fig. 2b,c) , suggesting a feed-forward/self-enabling loop.
AP-1 factors are classic proto-oncogenes and are important as tumour 'promoters' , cooperating with Ras 'initiating' mutations in skin chemical carcinogenesis 27, 29, 30 . Our findings suggest that part of these attributes could rely on the ability of AP-1 dimers to synergize with YAP/TAZ on chromatin. Supporting this notion, gain-of-AP-1 is per se insufficient to sustain oncogenic growth in the absence of YAP overexpression in mammary epithelial cells. In line, YAP/TAZ are genetically required for skin tumorigenesis on the classical tumour initiation/promotion protocol with DMBA/TPA. That said, further experiments are required to formally demonstrate the transcriptional cooperation between YAP/TAZ/TEAD and AP-1 in skin tumours.
The role of AP-1 proteins as general factors in YAP/TAZtranscriptional regulation adds a number of new modalities to feed information to the YAP/TAZ genetic program. For example, AP-1 proteins are activated by inflammation and stress inputs 20 , and these may sensitize cells to YAP/TAZ-inducing inputs 3 . Then, there is a widely reported implication of AP-1 in epithelial-mesenchymal transition (EMT), especially in breast cancer cells; for example, recent reports have linked high FOSL1 expression to EMT and metastasis 35, 36 . Given the established connections between YAP/TAZ and EMT/malignant traits 3 , it is thus tempting to speculate that AP-1 factors may cooperate with YAP/TAZ for metastatic dissemination or colonization.
It is also notable that AP-1 are dimers of variable composition, and do not always behave as oncogenes 20 , adding further complexity and potentially cell specificity to the effects of YAP/TAZ. Further studies are required to dissect these interplays in distinct biological contexts in which YAP/TAZ and AP-1 have been so far only independently implicated, including cancer, stem cell biology, regeneration and differentiation.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3216 METHODS Plasmids. pCS2-FLAG-mTAZ, pBABE-hygro-FLAG-mTAZ wt and S89A, pCDNA-FLAG-YAP, FU-tet-o-EGFP-ires-PURO, and 8xGTIIC-LUX were previously described 7, 16, 33, 37 TAZS51A and YAPS94A were generated by PCRmediated mutagenesis and cloned into pBABE retroviral vectors. pCMV6-FLAG-MYC-TEAD1 was from Origene. FU-tet-o-hc-myc (no. 19775, ref. 38 ) and FUdeltaGW-rtTA (no. 19780, ref. 38) were purchased from Addgene. pBABEpuro-JUN∼FOSL1-FLAG was a gift from L. Bakiri 26 . Doxycycline-inducible JUN-DN lentiviral construct was obtained by substituting the Oct4 sequence in FUW-tetO-hOCT4 (Addgene no. 20726) with JUN-DN cDNA from pMIEG3-JunDN (Addgene no. 40350). pAP1-luc was from Clontech and pRL-TK from Promega. CTGF and ANKRD1 luciferase reporters were generated by amplifying CTGF (hg19, chr6:132272417-132273191)/ANKRD1(chr10:92680870-92681128) promoters by PCR from genomic DNA and cloning into pGL3 basic; for AP-1 mutants, point mutations were introduced by PCR in AP-1-binding sites; for TEAD mutants, a single deletion comprising the three TEAD-binding sites was introduced in CTGF promoter, whereas point mutations were generated in the ANKRD1 promoter. All constructs were confirmed by sequencing. All cell lines were routinely tested for mycoplasma contamination and were negative. None of the cell lines used in this study is present in the database of commonly misidentified cell lines. A549 cells were cultured in DMEM/F12 (Life Technologies) supplemented with 10% FBS, glutamine and antibiotics; culture conditions for all of the other cell lines were as previously described 16, 39 . siRNAs were transfected with Lipofectamine RNAi-MAX (Life Technologies), and DNA transfections were performed with TransitLT1 (Mirus Bio) according to the manufacturer's instructions. Cells were collected 48 h after transfection, unless differently specified. Sequences of siRNAs are provided in Supplementary  Table 9 . Retroviral and lentiviral infections were carried out as in refs 40,41. MCF10A e.v. cells were infected with pBABE-puro and pBABE-blasti empty vectors; MCF10A+AP-1 were infected with pBABE-puro-JUN∼FOSL1-FLAG and pBABE-blasti empty vector; MCF10A+YAP (or 5SA/S94A) were infected with pBABE-puro empty vector and pBABE-blasti-FLAG-YAP5SA (or 5SA/S94A); MCF10A+YAP+AP-1 were infected with pBABE-puro-JUN∼FOSL1-FLAG and pBABE-blasti-FLAG-YAP5SA (or 5SA/S94A).
ChIP-seq, ChIP-qPCR and ChIP-reChIP. Chromatin immunoprecipitation was performed as described in ref. 42 Antibodies are listed in Supplementary Table 6 . Briefly, cells were crosslinked with 1% formaldehyde (Sigma) in culture medium for 10 min at room temperature, and chromatin from lysed nuclei was sheared to 200-600 bp fragments using a Branson Sonifier 450A. For ChIP-seq, ∼200 µg of chromatin was incubated with 10 µg of antibody overnight at 4 • C. Antibody/antigen complexes were recovered with ProteinA-Dynabeads (Invitrogen) for 2 h at 4 • C. ChIP' d DNA from 3 immunoprecipitations was pooled to generate libraries with the Ovation Ultra Low Library Prep Kit (NuGEN) according to the manufacturer's instructions. Sequencing was performed on an Illumina HiSeq 2500 platform.
For ChIP-qPCR, ∼100 µg of sheared chromatin and 3-5 µg of antibody were used. For ChIPs of modified histones, at least 50 µg of chromatin was incubated with 2 µg of antibody. Quantitative real-time PCR was carried out with a RotorGene Q (Qiagen) thermal cycler; each sample was analysed in triplicate. The amount of immunoprecipitated DNA in each sample was determined as the fraction of the input (amplification efficiencyˆ(Ct INPUT-Ct ChIP)), and normalized to the IgG control. Primers are listed in Supplementary Table 9. For ChIP-reChIP, MDA-MB-231 cells stably expressing FLAG-YAP5SA were used. Chromatin was incubated with anti-FLAG magnetic beads (Sigma) for 4 h at 4 • C; after washing, immunocomplexes were eluted by incubating beads in lysis buffer 3 + 0.5 µg µl −1 3× FLAG peptide (Sigma) for 1 h at 4 • C; two sequential elutions were performed. Eluted chromatin was diluted 1:3 with lysis buffer 3, supplemented with 1% Triton X-100 and incubated with 3 µg of normal mouse IgG or anti-JUN antibody, overnight at 4 • C.
Peak calling and data analysis. Raw reads were aligned using Bowtie (version 0.12.7; ref. 43 ) to build version hg19 of the human genome retaining only uniquely mapped reads. Redundant reads were removed using SAMtools. The IDR (Irreproducible Discovery Rate) framework 44 was used to assess the consistency of replicate experiments and to obtain a high-confidence single set of peak calls for each transcription factor as described in the ChIP-seq guidelines of the ENCODE consortium 45 . MACS2 version 2.0.10 (ref. 46 ) was used to call peaks in individual replicates using IgG ChIP-seq as the control sample and an IDR threshold of 0.01 was applied for all data sets to identify an optimal number of peaks.
Normalized read density (reads per million, rpm) was calculated from pooled replicates using the MACS2 callpeak function and displayed using the Integrative Genomics Viewer (IGV).
Heatmaps were generated using a custom R script that considers a 2-kb window centred on peak summits and calculates the normalized read density with a resolution of 50 bp.
The genomic location of the peaks and their distance to the TSS of annotated genes were calculated using the annotatePeakInBatch function of the ChIPpeakanno R package and GENCODE annotation version 16 (ref. 47) . Only genes classified as protein coding and with status equal to KNOWN were considered.
The findOverlappingPeaks function of the same package was used with default parameters to identify overlapping peaks and calculate the distance between their summits. TAZ peak coordinates and summit positions were used to represent common peaks between YAP and TAZ peaks (YAP/TAZ peaks) and were used when comparing YAP/TAZ peaks with other ChIP-seq data.
Definition of MDA-MB-231 promoters and enhancers. Raw reads for ChIP-seq data of histone modifications (H3K4me1, H3K4me3 and H3K27ac) in MDA-MB-231 (ref. 13) were downloaded from SRA (SRP028597) and aligned using Bowtie version 0.12.9 to build version hg19 of the human genome retaining only uniquely mapped reads. Redundant reads were removed using SAMtools. Peak calls and read density tracks were generated using SPP version 1.11 (ref. 48 ) with default parameters and using as the control sample the IgG ChIP-seq data generated in our laboratory because of the low sequencing depth of the input DNA contained in SRP028597.
The distance between histone modification peaks and the transcription start sites (TSSs) of protein-coding genes (GENCODE v. 16 and REFSEQ annotations), and the overlap between histone mark peaks were calculated as previously described for transcription factor peaks.
The presence of H3K4me1 and H3K4me3 peaks, their genomic locations and their overlap were the criteria used to define promoters and enhancers: H3K4me3 peaks not overlapping with H3K4me1 peaks and close to a TSS (±5 kb) were defined as promoters, as NA otherwise; H3K4me1 peaks not overlapping with H3K4me3 peaks were defined as enhancers; regions with the co-presence of H3K4me1 and H3K4me3 peaks were visually inspected on IGV and were defined as promoters, enhancers or NA after the evaluation of the proximity to a TSS and the comparison of the enrichment signals. Finally, promoters or enhancers were defined as active if overlapping with H3K27ac peaks. YAP/TAZ/TEAD peak annotation. YAP/TAZ/TEAD peaks were annotated as promoters or enhancers if their summit was overlapping with promoter or enhancer regions as defined above. Peaks with the summit falling in regions with no H3K4me1 or H3K4me3 peaks, or in NA regions were defined as 'not assigned' and discarded from subsequent analyses. YAP/TAZ/TEAD peak summits were compared with FAIRE peaks using the list downloaded from GSE49651.
YAP/TAZ/TEAD peaks falling on promoters were assigned to the closest TSS. YAP/TAZ/TEAD peaks falling on active enhancers were annotated using the chromatin interactions reported in Supplementary data 2 of ref. 14, derived from a high-resolution Hi-C experiment; the data sheets report the genomic locations of all target peaks interacting with more than 10,000 anchors located at gene promoters. YAP/TAZ peaks overlapping with these target peaks were assigned to the corresponding interacting promoter region. Finally, YAP/TAZ/TEAD peaks falling on inactive enhancers were not assigned to targets.
Motif discovery in ChIP-seq peaks. De novo motif discovery was performed with the findMotifsGenome function of Homer software 49 . Motifs were searched in 500 bp windows centred at the peak summits. Occurrences of de novo and known motifs inside the peaks were found using the annotatePeaks function of the same software. Known motifs were retrieved from the Homer motif database and from the JASPAR database (http://jaspar.genereg.net).
Gene expression analysis by Affymetrix microarrays. MDA-MB-231 cells were transfected with control or two independent combinations of YAP/TAZ siRNAs for 48 h; four biological replicates for each sample were prepared. Transcriptomic data were obtained using Affymetrix GeneChips Human Genome U133 Plus 2.0. Raw data were as in ref. 50 , but analysed as detailed below.
Microarray analyses were performed in R (version 2.15.1). Probe level signals were converted to expression values using the robust multi-array average procedure RMA (ref. 51 ) of the Bioconductor affy package and a custom chip definition file based on the Entrez gene database (version 17, ref. 52). Differentially expressed genes were identified using the Significance Analysis of Microarray algorithm coded in the samr R package 53 . In SAM, we estimated the percentage of false positive predictions DOI: 10.1038/ncb3216
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(that is, false discovery rate, FDR) with 100 permutations. To identify genes regulated by YAP/TAZ, we selected those genes coherently downregulated with a FDR ≤ 0.1% in both silencing experiments, and present in GENCODE v.16 annotation. This selection resulted in 1,534 downregulated genes. These genes were compared with the list of candidate YAP/TAZ direct target genes described above. As a result, 379 genes were defined as YAP/TAZ direct positive targets, as they were downregulated by YAP/TAZ depletion and associated with at least one YAP/TAZ peak.
Gene ontology analysis. Gene Ontology (GO) analyses were performed using DAVID (ref. 54) . The full list of GO terms of the Biological Process category enriched in direct positive YAP/TAZ targets is presented in Supplementary Table 4 . GO terms with a Benjamini-Hochberg FDR ≤ 5% were considered significantly enriched. GO terms significantly enriched among YAP/TAZ/TEAD direct positive target genes could be assigned to two broad categories: 'cell proliferation' and 'RNA metabolism and transport' (Supplementary Table 4) . Promoters of the genes involved in cell proliferation were defined as 1,000 bp windows centred at the TSS. De novo motif discovery and occurrence of known motifs were performed as described above. Used known motifs are E2F4(E2F) from the Homer motif database and (MA0024.1) for E2F1 from the JASPAR database.
Analysis of public ChIP-seq data. ChIP-seq data sets for transcription factors and histone modifications that were reanalysed in this study are listed in Supplementary Table 7 .
For data of the ENCODE project 21 , aligned reads and peak calls were downloaded from the ENCODE project repository. When available, transcription factor peaks uniformly generated by the ENCODE Analysis Working Group (available at http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/ wgEncodeAwgTfbsUniform) were used. Otherwise, aligned reads and peak calls of the first replicate were used. Genomic annotation of TEAD4 or TEAD1 peaks and overlap between peaks were calculated as described for ChIP-seq data of MDA-MB-231 cells. Reverse transcription and qPCR were performed as described in ref. 7 . Expression levels are normalized to GAPDH. Primers are listed in Supplementary  Table 9 . For the experiments in Figs 2b and 5a,h cDNA was synthesized with the High Capacity RNA-to-cDNA Kit (Invitrogen) and target genes were quantified with custom TaqMan Low Density Arrays on a 7900HT Fast Real-Time PCR System (Applied Biosystems), using TaqMan Universal PCR Master Mix (Applied Biosystems). TaqMan assays included in the array are listed in Supplementary  Table 9 . Expression levels are normalized to GAPDH.
Chromatin conformation capture (3C). 3C was performed as described in ref. 56 with some modifications. Adherent cells were incubated with a solution containing 1.5% formaldehyde for 10 min at room temperature, followed by 5 min treatment with 0.125 M glycine/PBS. Cells were incubated with 0.05% trypsin for 10 min at 37 • C, before completely detaching them with a cell scraper. Collected cells were pelletted, washed in PBS and incubated with lysis buffer for 15 min at 4 • C. Nuclei were digested with HindIII restriction enzyme (NEB), and highly diluted digested chromatin was ligated with T4 DNA ligase (NEB). De-crosslinked DNA fragments were purified by phenol-chloroform extraction and ethanol precipitation. A reference template was generated by digesting, mixing and ligating bacterial artificial chromosomes spanning the genomic regions of interest. 3C templates and the reference template were used to perform semiquantitative PCR with GO Taq G2 Flexi DNA Polymerase (Promega). Primers flanked the HindIII restriction sites located close to MYC and TOP2A promoters (anchors) and enhancers (primer sequences are provided in Supplementary Table 9 ). Data are presented as the ratio of amplification obtained with 3C templates from MDA-MB-231 cells and with the reference template. PCR performed on control 3C template obtained from not-crosslinked cells never yielded any product. PCR products were verified by sequencing.
Collection and processing of breast cancer gene expression data. We started from a collection of 4,640 samples from 27 major data sets comprising microarray data of breast cancer samples annotated with histological tumour grade and clinical outcome (Supplementary Table 8 ). The collection was normalized and annotated with clinical information as described in ref. 50 . This resulted in a compendium (meta-data set) comprising 3,661 unique samples from 25 independent cohorts (Supplementary Table 8 ).
Survival analysis. To identify two groups of tumours with either high or low YAP/TAZ/TEAD direct target gene signature we used the classifier described in ref. 55 , that is, a classification rule based on the YAP/TAZ/TEAD direct target gene signature score. Tumours were classified as 'YAP/TAZ/TEAD direct target gene signature' Low if the combined score was negative and as 'YAP/TAZ/TEAD direct target gene signature' High if the combined score was positive. To evaluate the prognostic value of the signature, we estimated, using the Kaplan-Meier method, the probabilities that patients would remain free of metastasis. The Kaplan-Meier curves were compared using the log-rank (Mantel-Cox) test. P values were calculated according to the standard normal asymptotic distribution. Survival analysis was performed in GraphPad Prism.
Average signature expression and correlation. Average signature expression has been calculated as the standardized average expression of all signature genes in sample subgroups. To test the association between YAP/TAZ/TEAD direct target gene signature, TAZ (WWTR1) expression level, and YAP/TAZ signatures 37, 57 , we calculated the Pearson's product moment correlation coefficient using the cor.test function of the stat R package. Western blot. Whole-cell lysates were obtained by sonication in lysis buffer (20 mM HEPES (pH 7.8), 100 mM NaCl, 5% glycerol, 5 mM EDTA, 0.5% Np40, and protease and phosphatase inhibitors). The western blot procedure was carried out as described in ref. 39 . Primary antibodies are listed in Supplementary Table 6 .
In situ proximity ligation assay. In situ PLA was performed with DuoLink In Situ Reagents from Olink Bioscience (Sigma). MDA-MB-231 cells were transfected with siRNAs in standard cell culture dishes, seeded in fibronectin-coated glass chamber slides 24 h later, and fixed in 4% PFA for 10 min at room temperature 48 h after transfection. Proximity ligation assays were performed as indicated by the provider's protocol, after an overnight incubation with primary antibodies following the immunofluorescence protocol described in ref. 37 . Images were acquired with a Leica SP5 confocal microscope equipped with a CCD camera; for each field, a Z-stack was acquired; images were processed using Volocity software (PerkinElmer). Primary antibodies are listed in Supplementary Table 6 . To determine the fraction of cells in each phase of the cell cycle, subconfluent cells were trypsinized 48 h after siRNA transfection, fixed in cold 70% ethanol and stained with 0.02 mg ml −1 propidium iodide + 0.2 mg ml −1 RNase A in PBS. Stained cells were analysed on a FC500 cytofluorimeter (Beckman Coulter).
Soft-agar and mammosphere assays. For soft-agar assay, 10 4 MCF10A cells in complete growth medium with 0.35% agar were layered onto 0.5% agar beds in sixwell plates; complete medium was added on top of cells and was replaced with fresh medium twice a week for 15 days. Colonies larger than 100 µm in diameter were counted as positive for growth. Thresholds were arbitrarily set to classify colonies according to their size.
For mammosphere formation assay, 1,000 cells cm −2 were seeded on ultralowattachment plates (Costar), in DMEM/F12 supplemented with 10 ng ml −1 EGF, DOI: 10.1038/ncb3216 5 µg ml −1 insulin, 0.5 µg ml −1 hydrocortisone, 52 µg ml −1 bovine pituitary extract and B27 supplement. Mammospheres were counted after one week.
Mice. Animal experiments were performed adhering to our institutional guidelines (CEASA, Comitato Etico per la Sperimentazione Animale, corresponding to our Animal Welfare Body).
For orthotopic transplantation experiments, MCF10A cells were injected into the abdominal mammary glands of 6-10-week-old RAG −/− female mice. For each injection, 10 6 cells were mixed 1:1 with Matrigel, in a final volume of 100 µl. Tumour growth in the injected site was monitored by repeated calliper measurements. Mice were euthanized after one month and tumours were explanted, fixed in 4% PFA and embedded in paraffin for histological analyses. The number of injections were: control (e.v.) n = 8, +AP-1 n = 10, +YAP n = 10, +YAP+AP-1 n = 12, +YAPS94A n = 6, +YAPS94A+AP-1 n = 6. Yap1 fl/fl mice were provided by D. Pan 58 . K14-CreERT2 mice were provided by P. Chambon 38 . Taz fl/fl mice were described in ref. 33 . Animals were genotyped with standard procedures 59 , and with the recommended set of primers. To selectively ablate YAP/TAZ in epidermal keratinocytes of adult mice, mice carrying LoxPsite-containing Yap and Taz alleles were bred with hemizygous K14-CreERT2 tg /0 transgenic mice, to produce K14-CreERT2 tg /0 ; Yap fl/fl ; Taz fl/+ . 6-8-week-old mice (4 females and 5 males in each experimental group) received 3 intraperitoneal injections of tamoxifen (1 mg in 100 µl corn oil) to produce control (from K14-CreERT2 tg/0 ) or conditional Yap/Taz KO mice (from K14-CreERT2 tg/0 ; Yap fl/fl ; Taz fl/+ ). Two weeks after tamoxifen injection, mice were shaved to synchronize the hair cycle and treated the day after with a single dose of DMBA (Sigma, 100 µg in 100 µl acetone). One week after DMBA application, TPA (Sigma, 5 µg in 100 µl acetone) was applied topically twice a week for up to 40 weeks. The number of tumours per mouse was recorded weekly. Tumours or skin explants were excised at the end of the DMBA/TPA treatment, fixed in 4% PFA and embedded in paraffin for histological sections. DNA was extracted from skin and genotyped with the recommended set of primers for Yap null allele (as in ref. 58) , Taz null allele (as in ref. 33 ) and K14-CreERT2 (for: 5 -TGGGAAAGTGTAGCCTGCAG-3 ; rev: 5 -T CCCCTTGGCTTTCATCACC-3 ; 182 bp).
All tested animals were included; no statistical method was used to predetermine sample size; no randomization or blinding was used.
Immunohistochemistry.
Immunohistochemical staining was performed as described in ref. 60 . Primary antibodies were anti-human Ki67 (Dako, M7240) and anti-human cytokeratin (Dako, M0821).
Reproducibility of experiments.
ChIP-seq experiments contained two biological replicates, obtained from two independent experiments. For ChIP-qPCR, at least two independent experiments (each containing 2 biological replicates) were performed with similar results. For gene expression analysis with Affymetrix Microarrays four biological replicates were analysed for each sample. For qRT-PCR, 3 independent experiments (each with 2 biological replicates) were performed, with similar results. 3C experiments contained n = 3 biological replicates and were repeated twice with similar results. Co-immunoprecipitation assays, DNA pulldown, western blots and PLA assays were performed three times with similar results. For luciferase assays, each experiment contained 2 biological replicates and was repeated at least three times independently with similar results. For growth assays, 8 independent replicate wells were analysed for each sample; each experiment was performed at least twice, with similar results. For cell cycle analysis, experiments contained n = 3 biological replicates for each condition, and were repeated at least twice with similar results. Soft-agar assays contained n = 3 biological replicates for each condition and were performed three times, with similar results. Mammosphere assays contained n = 6 biological replicates for each condition and were performed three times, with similar results.
Luciferase data are presented as mean + s.d. of n = 4 biological replicates from 2 experiments.
For all other experiments, results from one representative experiment are shown.
Accession numbers. ChIP-seq data is stored in the Gene Expression Omnibus under accession number GSE66081 for and gene expression data under GSE66082. All data from this study have been deposited in the GEO database under accession number GSE66083. Accession numbers for public ChIP-seq and gene expression data sets used in this study are reported in Supplementary Tables 7 and 8 wt mut wt
